Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder

References

• RushAJTrivediMHWisniewskiSRAcute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D ReportAm J Psychiatry2006163111905191717074942
   PubMed Web of Science ®Google Scholar
• TrivediMHRushAJWisniewskiSREvaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practiceAm J Psychiatry20061631284016390886
   PubMed Web of Science ®Google Scholar
• FavaMRushAJCurrent status of augmentation and combination treatments for major depressive disorder: A literature review and a proposal for a novel approach to improve practicePsychother Psychosom200675313915316636629
   PubMed Web of Science ®Google Scholar
• American Psychiatric AssociationPractice Guideline for the Treatment of Patients With Major Depressive Disorder2nd edArlington, VAAmerican Psychiatric Association2000
   Google Scholar
• BermanRMMarcusRNSwaninkRThe efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled studyJ Clin Psychiatry200768684385317592907
   PubMed Web of Science ®Google Scholar
• MarcusRNMcQuadeRDCarsonWHThe efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A second multicenter, randomized, double-blind, placebo-controlled studyJ Clin Psychopharmacol200828215616518344725
   PubMed Web of Science ®Google Scholar
• BermanRFavaMThaseMAripiprazole augmentation in major depressive disorder: A double-blind, placebo-controlled study in patients with inadequate response to antidepressantsCNS Spectr200914419720619407731
   PubMed Web of Science ®Google Scholar
• MarderSRMcQuadeRDStockEAripiprazole in the treatment of schizophrenia: Safety and tolerability in short-term, placebo-controlled trialsSchizophr Res2003612–312313612729864
   PubMed Web of Science ®Google Scholar
• MarcusRNCarsonWHMcQuadeRDOverview of safety and tolerability of aripiprazole in acute maniaPaper presented at the annual meeting of the American Psychiatric AssociationMay 1–6, 2004New York, NY
   Google Scholar
• FavaMWeight gain and antidepressantsJ Clin Psychiatry200061Suppl 11374110926053
   PubMed Web of Science ®Google Scholar
• SuppesTMcElroySLHirschfeldRAwareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder: A survey of 500 US psychiatristsPsychopharmacol Bull2007402223717514184
   PubMedGoogle Scholar
• SheltonRCWilliamsonDJCoryaSAOlanzapine/fluoxetine combination for treatment-resistant depression: A controlled study of SSRI and nortriptyline resistanceJ Clin Psychiatry200566101289129716259543
   PubMed Web of Science ®Google Scholar
• RapaportMHGharabawiGMCanusoCMEffects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuationNeuropsychopharmacology200631112505251316760927
   PubMed Web of Science ®Google Scholar
• ThaseMECoryaSAOsuntokunOA randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorderJ Clin Psychiatry200768222423617335320
   PubMed Web of Science ®Google Scholar
• MontgomerySAAsbergMA new depression scale designed to be sensitive to changeBr J Psychiatry1979134382389444788
   PubMed Web of Science ®Google Scholar
• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text RevisionWashington, DCAmerican Psychiatric Association2000
   Google Scholar
• FavaMDiagnosis and definition of treatment-resistant depressionBiol Psychiatry200353864965912706951
   PubMed Web of Science ®Google Scholar
• HamiltonMA rating scale for depressionJ Neurol Neurosurg Psychiatry196023566214399272
   PubMed Web of Science ®Google Scholar
• GuyWClinical Global Impressions (CGI)US Department of Health, Education, and Welfare Publication (ADM) 76-338ECDEU Assessment Manual for PsychopharmacologyRockville, MDNational Institute of Mental Health1976
   Google Scholar
• SimpsonGMAngusJWA rating scale for extrapyramidal side effectsActa Psychiatr Scand Suppl197021211194917967
   PubMedGoogle Scholar
• BarnesTRA rating scale for drug-induced akathisiaBr J Psychiatry19891546726762574607
   PubMed Web of Science ®Google Scholar
• GuyWAbnormal Involuntary Movement Scale (AIMS)US Department of Health, Education, and Welfare publication (ADM) 76-338ECDEU Assessment Manual for PsychopharmacologyRockville, MDNational Institute of Mental Health1976
   Google Scholar
• NelsonJCThaseMETrivediMHSafety and tolerability of adjunctive aripiprazole in major depressive disorder: A pooled post hoc analysis (studies CN138-139 and CN138-163)Prim Care Companion J Clin Psychiatry200911634435220098527
   PubMedGoogle Scholar
• ByerlyMSuppesTTranQVBakerRAClinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: Recent developments and current perspectivesJ Clin Psychopharmacol200727663966118004132
   PubMed Web of Science ®Google Scholar
• MichelsonDAmsterdamJDQuitkinFMChanges in weight during a 1-year trial of fluoxetineAm J Psychiatry199915681170117610450256
   PubMed Web of Science ®Google Scholar
• WiseTNPerahiaDGPangalloBALosinWGWiltseCGEffects of the antidepressant duloxetine on body weight: Analyses of 10 clinical studiesPrim Care Companion J Clin Psychiatry20068526927817235383
   PubMedGoogle Scholar
• WadeADespiegelNHeldbo ReinesEEscitalopram in the long-term treatment of major depressive disorderAnn Clin Psychiatry2006182838916754413
   PubMedGoogle Scholar
• MasandPSGuptaSLong-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapineAnn Clin Psychiatry200214317518212585567
   PubMedGoogle Scholar